Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

stance and the improved patient comfort due to lower PONV supports CeNeS justification of a substantial price premium for M6G compared to morphine.

We are actively pursuing potential partners for M6G and are confident that agreements can be reached. We are well positioned to deliver significant value to shareholders by the successful commercialisation of M6G".

- END -

CeNeS Pharmaceuticals plc will be announcing its preliminary results for the year ended 31 December 2006 on Wednesday 28 March 2007. On the same day the Company will be hosting an R&D presentation at the offices of Financial Dynamics. The presentation will start at 9:30am and is expected to conclude at 11am.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: www.cenes.com

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have sho
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... today announced the relocation of their corporate headquarters from Clearwater, ... CCS Medical has more than 1,500 employees in seven offices ... home healthcare products and services to patients with chronic conditions ... our corporate relocation was an easy choice. The state of ...
... Sept. 30, 2011 Roche announced today the opening ... its campus in Nutley, N.J. The Roche Center of ... preclinical safety studies, and Phase 1 and 2 clinical ... to process potent compounds into medicines for clinical trials. ...
Cached Medicine Technology:CCS Medical Relocating Corporate Headquarters to DFW Metroplex 2CCS Medical Relocating Corporate Headquarters to DFW Metroplex 3Roche Opens New Center of Excellence Facility 2
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... not only for tomato lovers around the country but also ... for millions of people. , In research published June 4 ... they,ve identified a molecular trick that may explain part of ... Medical Center has identified a protein that allows the bacteria ...
... Detection of Brain Injury Is Key, WASHINGTON, ... Rehabilitation Hospital (NRH) will fly to Germany on ... Medical Command (ERMC), in,assessing their current rehabilitation practices. ... and delivery of care given to,injured soldiers and ...
... Birner Dental Management,Services, Inc. (Nasdaq: BDMS ... regular quarterly dividend. The Company,s board of directors,has ... per share of common,stock. The dividend is payable ... 2008., Birner Dental Management Services, Inc. acquires, ...
... over next 60 days to try to resolve remaining ... company,PreMD Inc. (TSX: PMD; Amex: PME) today announced that ... and Drug Administration (FDA) in an,effort to resolve the ... non-invasive skin cholesterol test. Over the,next 60 days PreMD ...
... they fret about kids, knowledge of safety, privacy, emergency practices, ... (HealthDay News) -- Many parents leave their tweens home alone ... not confident these 11- to 13-year-olds have the knowledge or ... The University of Michigan C.S. Mott Children,s Hospital National Poll ...
... to Narconon,Trois-Rivieres, drug addiction is not a random ... in most instances by a problem, a particular,discomfort, ... individual,cannot handle or fix. The individual will find ... *(PHOTO Link: Send2Press.com/mediaboom/08-0613-Narconon_72dpi.jpg), (Photo Caption: Drug ...
Cached Medicine News:Health News:Salmonella: Trickier than we imagined 2Health News:Salmonella: Trickier than we imagined 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:PreMD Reports Further Positive Meetings with the FDA 2Health News:Parents Worry About Tweens Left Alone 2Health News:Drug Addiction Explained by Drug Addiction Center 2
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... WorkCell System - A Single Platform ... hour, with true load-and-go productivity and ... Atlas and UF-100 for complete walkaway ... working together deliver utmost reliability. Ease ...
... high throughput primary or backup instrument, ... performance and reliability equal to or ... The advanced technology of the AUTION ... delivers reproducible and accurate results, limiting ...
... of the 3 major naturally occurring estrogens ... terms of estrogenic activity, estriol is much ... produced almost exclusively during pregnancy, and is ... human fetus. During pregnancy, the production of ...
Medicine Products: